News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
745,331 Results
Type
Article (53565)
Company Profile (666)
Press Release (691100)
Multimedia
Podcasts (102)
Webinars (14)
Section
Business (211424)
Career Advice (3385)
Deals (37524)
Drug Delivery (121)
Drug Development (85049)
Employer Resources (185)
FDA (17109)
Job Trends (16287)
News (361256)
Policy (34748)
Tag
Academia (2801)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (95)
Alliances (51971)
ALS (105)
Alzheimer's disease (1487)
Antibody-drug conjugate (ADC) (161)
Approvals (17063)
Artificial intelligence (296)
Autoimmune disease (29)
Automation (17)
Bankruptcy (388)
Best Places to Work (12309)
BIOSECURE Act (22)
Biosimilars (114)
Biotechnology (460)
Bladder cancer (85)
Brain cancer (31)
Breast cancer (311)
Cancer (2467)
Cardiovascular disease (203)
Career advice (2859)
Career pathing (34)
CAR-T (177)
Cell therapy (494)
Cervical cancer (21)
Clinical research (68972)
Collaboration (929)
Company closure (2)
Compensation (578)
Complete response letters (30)
COVID-19 (2789)
CRISPR (50)
C-suite (275)
Cystic fibrosis (108)
Data (2367)
Decentralized trials (2)
Denatured (29)
Depression (54)
Diabetes (297)
Diagnostics (6798)
Digital health (20)
Diversity (6)
Diversity, equity & inclusion (45)
Drug discovery (133)
Drug pricing (123)
Drug shortages (32)
Duchenne muscular dystrophy (104)
Earnings (86286)
Editorial (47)
Employer branding (24)
Employer resources (158)
Events (122910)
Executive appointments (781)
FDA (18509)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (821)
Gene editing (125)
Generative AI (26)
Gene therapy (366)
GLP-1 (841)
Government (4751)
Grass and pollen (6)
Guidances (154)
Healthcare (19945)
Huntington's disease (24)
IgA nephropathy (31)
Immunology and inflammation (151)
Indications (30)
Infectious disease (2946)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (54)
Intellectual property (102)
Interviews (664)
IPO (17502)
IRA (49)
Job creations (4467)
Job search strategy (2337)
Kidney cancer (10)
Labor market (44)
Layoffs (556)
Leadership (24)
Legal (8391)
Liver cancer (82)
Lung cancer (346)
Lymphoma (160)
Machine learning (9)
Management (62)
Manufacturing (362)
MASH (84)
Medical device (14359)
Medtech (14364)
Mergers & acquisitions (20602)
Metabolic disorders (793)
Multiple sclerosis (90)
NASH (23)
Neurodegenerative disease (118)
Neuropsychiatric disorders (34)
Neuroscience (2097)
NextGen: Class of 2025 (7280)
Non-profit (4576)
Now hiring (41)
Obesity (424)
Opinion (273)
Ovarian cancer (82)
Pain (104)
Pancreatic cancer (90)
Parkinson's disease (161)
Partnered (23)
Patents (254)
Patient recruitment (118)
Peanut (51)
People (61117)
Pharmaceutical (133)
Pharmacy benefit managers (22)
Phase I (21578)
Phase II (30401)
Phase III (22793)
Pipeline (1404)
Policy (177)
Postmarket research (2545)
Preclinical (9186)
Press Release (69)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (270)
Rare diseases (435)
Real estate (6541)
Recruiting (73)
Regulatory (23925)
Reports (42)
Research institute (2504)
Resumes & cover letters (537)
Rett syndrome (6)
RNA editing (5)
RSV (49)
Schizophrenia (81)
Series A (144)
Series B (94)
Service/supplier (26)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (157)
Sponsored (34)
Startups (4054)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (53)
The Weekly (72)
Vaccines (803)
Venture capitalists (45)
Weight loss (294)
Women's health (35)
Worklife (20)
Date
Today (66)
Last 7 days (1004)
Last 30 days (3155)
Last 365 days (34612)
2025 (12481)
2024 (37575)
2023 (42214)
2022 (53469)
2021 (58052)
2020 (56510)
2019 (49464)
2018 (37631)
2017 (35501)
2016 (35418)
2015 (41159)
2014 (34187)
2013 (28883)
2012 (30578)
2011 (30905)
2010 (28597)
Location
Africa (982)
Alabama (61)
Alaska (7)
Arizona (214)
Arkansas (14)
Asia (44360)
Australia (7461)
California (6664)
Canada (2103)
China (576)
Colorado (286)
Connecticut (303)
Delaware (166)
Europe (99202)
Florida (977)
Georgia (224)
Hawaii (1)
Idaho (60)
Illinois (611)
India (29)
Indiana (342)
Iowa (12)
Japan (175)
Kansas (108)
Kentucky (26)
Louisiana (14)
Maine (66)
Maryland (937)
Massachusetts (5102)
Michigan (247)
Minnesota (427)
Mississippi (2)
Missouri (91)
Montana (31)
Nebraska (25)
Nevada (67)
New Hampshire (68)
New Jersey (1873)
New Mexico (31)
New York (1877)
North Carolina (1132)
North Dakota (8)
Northern California (2880)
Ohio (220)
Oklahoma (15)
Oregon (46)
Pennsylvania (1459)
Puerto Rico (14)
Rhode Island (36)
South America (1361)
South Carolina (25)
South Dakota (1)
Southern California (2475)
Tennessee (104)
Texas (991)
United States (25248)
Utah (197)
Virginia (170)
Washington D.C. (70)
Washington State (611)
West Virginia (3)
Wisconsin (67)
745,331 Results for "the emmes company llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Emmes Group® names Germaine Gross Chief Commercial Officer of Emmes® Biopharma
January 16, 2025
·
3 min read
Drug Development
ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
ILiAD Biotechnologies, LLC today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.
June 24, 2024
·
4 min read
Press Releases
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
April 22, 2025
·
2 min read
Press Releases
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - April 25, 2025
April 28, 2025
·
3 min read
Press Releases
Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
May 7, 2025
·
5 min read
Press Releases
Innovative Lab Services LLC Acquires Compco Analytical, Inc.
May 1, 2025
·
1 min read
Press Releases
ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts
March 5, 2025
·
6 min read
Press Releases
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
January 21, 2025
·
7 min read
Press Releases
ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference
March 18, 2025
·
7 min read
Press Releases
ITF Therapeutics LLC Announces Multiple Data Presentations at 2025 MDA Clinical and Scientific Conference
February 21, 2025
·
7 min read
1 of 74,534
Next
